Cardo Medical Announces Femur-First Versatility With Its Uni-Compartmental Knee System
Published: Feb 18, 2009
LOS ANGELES, CA--(Marketwire - February 18, 2009) - Cardo Medical (OTCBB: CDOM), a company engaged in the development of orthopedic medical devices, announces the femur-first versatility in surgical technique with its Uni-Compartmental Knee System. Uni-compartmental knee arthroplasty procedures are most commonly performed using tibial-first referencing surgical techniques; however the Cardo Medical Uni-Compartmental Knee system also provides surgeons with additional intra-operative versatility to easily adapt to femur-first surgical techniques. Dr. Andrew Yun, an orthopedic surgeon at St. John's Hospital in Santa Monica, CA, has performed numerous femur-first uni-compartmental arthroplasty procedures and commented, "I have been very satisfied with the ease of use and outcomes with this system. The Cardo engineering team has been incredible to work with, and I have enjoyed the responsiveness and quality of work which comes from this group." In addition, Dr. Jonathan Braslow, an orthopedic surgeon at JFK Memorial Hospital in Indio, CA, also stated, "The Cardo Align 360 instrumentation system eliminates the guesswork for the first cut, the system was easy and simple to use and creates a reproducible outcome each time." The Align 360 Uni-Compartmental Knee System, Cardo Medical's initial product release, has been used successfully since its introduction in January 2007. System enhancements for the femur-first approach include novel, unique femoral tibial alignment ("knee jack") instruments with dedicated alignment and resection guides.
Dr. Andrew Brooks, Chairman and Chief Executive Officer of Cardo Medical, stated, "The Cardo Medical Uni-Compartmental Knee system was our first commercially available arthroplasty system, and also set the standards of simplicity, versatility and reproducibility we design into all our system offerings. The Align 360 Uni-Compartmental Knee system enables surgeons the flexibility to choose between both a tibial-first or femoral-first referencing and resection surgical technique and approach. With its innovative alignment and conservative resection instrumentation, the system easily adapts to any surgeons' training and methodology, including use with mechanical or computer assisted surgical navigation. We are pleased to offer intra-operative versatility within all of our systems and continue to offer modularity and interchangeability, especially within our Align 360 knee platform. Our innovations especially with regards to instrumentation, surgical approaches and techniques enable surgeons to achieve excellent surgical outcomes."
About Cardo Medical, Inc.
Cardo Medical (OTCBB: CDOM) develops reconstructive orthopedic and spinal surgery products through advanced engineering and focuses on product development, marketing and distribution within the US market. Cardo Medical's superior engineering talent closely collaborates with leading surgeons around the country to create products that reduce or eliminate joint pain and allow patients to achieve more active lives. The company's cutting edge products are specifically developed with patients, surgeons and OR staff in mind and are designed to reduce operative time, enhance surgical technique, shorten hospital stays, reduce recovery time and improve outcomes. Cardo Medical's product portfolio includes devices for knee, hip, spinal fusion and motion preservation arthroplasty and replacement, many of which have already received FDA clearance. Cardo Medical has a robust and innovative product pipeline pending both USPTO and FDA submission and clearance.
Cardo Medical works in small, focused development teams in concert with physicians to rapidly develop products from concept to launch. We are committed to exceeding the standards by which any device company is judged. Please visit our website at www.cardomedical.com for more information on the Align 360 Uni-Compartmental Knee System in addition to our portfolio of other Reconstructive and Spinal Implant systems.
This press release contains "forward-looking statements," as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), regarding product development efforts and other non-historical facts about expectations, beliefs or intentions regarding the business, technologies and products, financial condition, strategies or prospects. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that any products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the ailments being studied or for other ailments. In addition, forward-looking statements also may be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. We do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
Cardo Medical, Inc.
Andrew A. Brooks, M.D.